Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
or

Envveno Medical Corp (NVNO)

Envveno Medical Corp (NVNO)
3.82 +0.23 (+6.41%) 16:00 ET [NASDAQ]
3.31 x 200 4.00 x 100
Realtime by (Cboe BZX)
3.31 x 200 4.00 x 100
Realtime - - (-) -
Quote Overview for Thu, Feb 20th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
3.48
Day High
3.85
Open 3.60
Previous Close 3.59 3.59
Volume 137,509 137,509
Avg Vol 95,178 95,178
Stochastic %K 79.67% 79.67%
Weighted Alpha -22.65 -22.65
5-Day Change +0.51 (+15.36%) +0.51 (+15.36%)
52-Week Range 2.45 - 6.97 2.45 - 6.97
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 62,954
  • Shares Outstanding, K 17,536
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,520 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 1.22
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.30

Options Overview Details

View History
  • Implied Volatility 226.66% ( -31.07%)
  • Historical Volatility 49.14%
  • IV Percentile 77%
  • IV Rank 34.78%
  • IV High 632.75% on 01/13/25
  • IV Low 10.14% on 06/14/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 50
  • Volume Avg (30-Day) 143
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 5,724
  • Open Int (30-Day) 3,929

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.32
  • Growth Rate Est. (year over year) +312,287.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.98 +28.52%
on 02/11/25
Period Open: 3.29
3.83 unch
on 02/20/25
+0.54 (+16.41%)
since 01/17/25
3-Month
2.45 +56.33%
on 12/20/24
Period Open: 3.37
3.83 unch
on 02/20/25
+0.46 (+13.65%)
since 11/20/24
52-Week
2.45 +56.33%
on 12/20/24
Period Open: 5.52
6.97 -45.05%
on 02/29/24
-1.69 (-30.62%)
since 02/20/24

Most Recent Stories

More News
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

On-demand video webcast now available here

NVNO : 3.82 (+6.41%)
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies here

AKTX : 1.0550 (-0.47%)
AREC : 0.5743 (-2.25%)
OTLK : 1.6400 (-3.24%)
AMIX : 2.93 (+2.09%)
CNSP : 0.0750 (-10.50%)
PALI : 0.9800 (+0.37%)
NVNO : 3.82 (+6.41%)
HURA : 3.30 (+3.77%)
GRI : 0.4352 (-17.90%)
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life (QoL) indicators.

NVNO : 3.82 (+6.41%)
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.

NVNO : 3.82 (+6.41%)
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Successful Completion of All Planned Implants in GLP Study

NVNO : 3.82 (+6.41%)
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Interviews with participating patients from the VenoValve® U.S. Pivotal Trial

NVNO : 3.82 (+6.41%)
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

85% Clinical Meaningful Benefit Responder Rate

NVNO : 3.82 (+6.41%)
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Definitive One Year Data from PMA Application to be Presented Wednesday at 51st Annual VEITH Symposium

NVNO : 3.82 (+6.41%)
enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH Symposium

- Interviews with patients from the VenoValve® pivotal study

NVNO : 3.82 (+6.41%)
enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH Symposium

IRVINE, CA / ACCESSWIRE / November 16, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today...

NVNO : 3.82 (+6.41%)

Business Summary

enVVeno Medical Corporation is a medical device company. It focuses in the treatment of venous disease. enVVeno Medical Corporation, formerly known as Hancock Jaffe Laboratories Inc., is based in IRVINE, CA.

See More

Key Turning Points

3rd Resistance Point 3.88
2nd Resistance Point 3.78
1st Resistance Point 3.69
Last Price 3.82
1st Support Level 3.50
2nd Support Level 3.40
3rd Support Level 3.31

See More

52-Week High 6.97
Fibonacci 61.8% 5.24
Fibonacci 50% 4.71
Fibonacci 38.2% 4.18
Last Price 3.82
52-Week Low 2.45

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements